What it's for (Indications)
- Rosuvastatin + ezetimibe combination therapy is indicated as an adjunct to diet for the treatment of primary hypercholesterolemia (including heterozygous familial hypercholesterolemia) or mixed dyslipidemia in adult patients when treatment with a statin alone or ezetimibe alone is not sufficient, or in patients already controlled with rosuvastatin and ezetimibe administered as separate components.
- This combination is also indicated for homozygous familial hypercholesterolemia to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (ApoB) levels, as an adjunct to other lipid-lowering treatments (e.
- g.
- , LDL apheresis) or if such treatments are unavailable.
- Furthermore, this medication plays a crucial role in reducing the risk of cardiovascular events, such as myocardial infarction and stroke, in patients at high risk due to existing atherosclerotic cardiovascular disease or multiple risk factors.
- Its comprehensive action addresses various aspects of lipid metabolism to achieve optimal cholesterol reduction and cardiovascular protection.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of rosuvastatin + ezetimibe must be individualized based on the patient's baseline lipid levels, established cardiovascular risk, and the target lipid goals, considering the patient's response and tolerability to treatment. The combination is typically administered as a single oral dose once daily, with or without food. Available strengths combine rosuvastatin (e.g., 5mg, 10mg, 20mg) with a fixed dose of ezetimibe (10mg). Patients should be placed on a standard cholesterol-lowering diet before starting treatment and should continue this diet during therapy. For patients requiring significant LDL-C reduction, the starting dose may be adjusted accordingly, with subsequent titration every 2 to 4 weeks if needed, guided by lipid panel assessments. The maximum recommended daily dose for rosuvastatin is 40 mg, so the combination product should not exceed this rosuvastatin component dose. Special populations, including patients with severe renal impairment (CrCl <30 mL/min) or Asian patients, may require lower starting doses and careful titration due to increased rosuvastatin exposure. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects for rosuvastatin + ezetimibe can include musculoskeletal pain such as myalgia, headache, asthenia (weakness or lack of energy), abdominal pain, nausea, and constipation or diarrhea.
- Patients may also experience nasopharyngitis, upper respiratory tract infection, or arthralgia.
- While generally well-tolerated, more serious adverse effects, though rare, warrant immediate medical attention.
- These include myopathy and rhabdomyolysis, characterized by severe muscle pain, weakness, and elevated creatine kinase (CK) levels, potentially leading to renal failure.
- Liver enzyme elevations (transaminases) can occur and should be monitored; severe hepatotoxicity is rare but serious.
- Other potential serious side effects include hypersensitivity reactions suchs as rash, urticaria, and angioedema.
- There is also a small increased risk of new-onset diabetes mellitus, particularly in patients with pre-existing risk factors.
- Patients should be counseled to report any unusual muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever.
Serious Warnings
- Black Box Warning: This medication does not carry an FDA-mandated Black Box Warning. However, healthcare professionals and patients must be acutely aware of severe potential adverse reactions that warrant immediate attention and often necessitate drug discontinuation. The most critical concerns include severe myopathy and rhabdomyolysis, which can lead to acute kidney injury due to myoglobinuria. Patients should be rigorously monitored for muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever, and creatine kinase levels should be checked promptly in such instances. Additionally, significant hepatic dysfunction, manifesting as persistent elevations of serum transaminases above three times the upper limit of normal, is a serious risk that requires discontinuation of therapy and careful evaluation of liver function. Rosuvastatin + ezetimibe is absolutely contraindicated during pregnancy and lactation due to the potential for fetal harm and excretion into breast milk, emphasizing the necessity for effective contraception in women of childbearing potential and avoidance in nursing mothers.
- Patients receiving rosuvastatin + ezetimibe therapy are at risk for developing myopathy and rhabdomyolysis, which can lead to acute renal failure secondary to myoglobinuria.
- This risk is dose-dependent with rosuvastatin and increased by concomitant use of drugs like cyclosporine, gemfibrozil, or high doses of niacin, and in patients with predisposing factors such as advanced age, renal impairment, or uncontrolled hypothyroidism.
- Liver enzyme elevations have been reported; persistent elevations of serum transaminases (ALT or AST >3 times the upper limit of normal) necessitate discontinuation of the drug.
- Liver function tests should be performed before initiating therapy and at appropriate intervals thereafter.
- Caution should be exercised in patients with a history of liver disease or heavy alcohol consumption.
- There is also a small but statistically significant increase in new-onset diabetes mellitus observed with statin use, particularly in patients with existing risk factors for diabetes.
- Patients should be advised to report any unexplained muscle pain, tenderness, or weakness immediately.
- Rosuvastatin + ezetimibe is contraindicated in pregnant or nursing women, as statins can cause fetal harm and are excreted in breast milk.
How it Works (Mechanism of Action)
The therapeutic efficacy of rosuvastatin + ezetimibe stems from their synergistic and complementary mechanisms of action in lowering cholesterol. Rosuvastatin, a potent HMG-CoA reductase inhibitor, blocks the rate-limiting step in endogenous cholesterol synthesis in the liver. This inhibition leads to a compensatory increase in the number of hepatic LDL receptors on the cell surface, enhancing the uptake and catabolism of circulating LDL-C. Rosuvastatin also reduces hepatic production of very-low-density lipoprotein (VLDL) and triglycerides. Ezetimibe, on the other hand, acts by selectively inhibiting the absorption of dietary and biliary cholesterol by the small intestine without affecting the absorption of fat-soluble vitamins, triglycerides, or bile acids. It achieves this by binding to the Niemann-Pick C1-Like 1 (NPC1L1) protein, a critical mediator of cholesterol absorption. The combined action of reducing both cholesterol synthesis (rosuvastatin) and cholesterol absorption (ezetimibe) results in a more significant reduction in LDL-C than either agent alone, offering a comprehensive approach to lipid management.
Commercial Brands (Alternatives)
No other brands found for this formula.